CC
DYN icon

Casdin Capital’s Dyne Therapeutics DYN Stock Holding History

Casdin Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$1.05M – 35
2025
Q1 		$1.05M Buy
+100,000
New +$1.43M 0.09% 36
2021
Q2 		– Sell
-610,000
Closed -$9.47M – 57
2021
Q1 		$9.47M Buy
610,000
+240,000
+65% +$4.64M 0.28% 40
2020
Q4 		$7.77M Hold
370,000
– – 0.23% 46
2020
Q3 		$7.47M Buy
+370,000
New +$8.12M 0.33% 40

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital's DYN Position: Q2 2025 in Review

Casdin Capital sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 100,000 shares — an estimated $1.05M sold.

Casdin Capital first reported a position in DYN in Q3 2020 and held it in 4 quarters. The position peaked at $9.47M in Q1 2021. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • Casdin Capital reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Casdin Capital sold 100,000 Dyne Therapeutics shares in Q2 2025, an estimated $1.05M.
  • Casdin Capital first reported a position in Dyne Therapeutics in Q3 2020 and held it in 4 quarters.
  • Casdin Capital's Dyne Therapeutics position peaked at $9.47M in Q1 2021.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Casdin Capital's 13F filing for Q2 2025, filed 14 Aug 2025.